Innate Pharma S.A.
IPHA
$2.03
$0.021.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.85% | -61.89% | |||
| Total Other Revenue | 7.84% | -8.67% | |||
| Total Revenue | 7.85% | -38.30% | |||
| Cost of Revenue | 7.85% | -11.55% | |||
| Gross Profit | -7.85% | -2.19% | |||
| SG&A Expenses | 7.85% | -4.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.85% | -9.50% | |||
| Operating Income | -7.85% | 0.63% | |||
| Income Before Tax | -7.85% | 14.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.85% | 14.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.85% | 14.72% | |||
| EBIT | -7.85% | 0.63% | |||
| EBITDA | -7.85% | -0.12% | |||
| EPS Basic | -7.82% | 20.30% | |||
| Normalized Basic EPS | -7.93% | 20.34% | |||
| EPS Diluted | -7.91% | 18.88% | |||
| Normalized Diluted EPS | -7.93% | 20.34% | |||
| Average Basic Shares Outstanding | 0.00% | 7.02% | |||
| Average Diluted Shares Outstanding | 0.00% | 7.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||